



Liste des publications IUCT-O/CRCT

Juin 2023

Version du 04/07/2023
(IF 2021)

1. Al-Emadi, I., Prudhomme, T., Sallusto, F., Hebral, A.-L., Lagarde, S., Thoulouzan, M., Game, X., Kamar, N., Soulie, M., Roumiguie, M., Doumerc, N., 2023. **Orthotopic Robot-Assisted Laparoscopic Kidney Transplantation with Living Donor: An option for patients excluded from standard heterotopic transplantation.** Am J Transplant S1600-6135(23)00525-7. <https://doi.org/10.1016/j.ajt.2023.06.001> - **cat A - IF : 9.639**
2. Algrin, C., Pérol, L., Chapiro, E., Baseggio, L., Maloum, K., Settegrana, C., Lesesve, J.-F., Siavellis, J., Delmer, A., Michallet, A.-S., Ferrant, E., Feugier, P., Tomowiak, C., Brion, A., Ghez, D., Fornecker, L.-M., Ivanoff, S., Struski, S., Sutton, L., Radford-Weiss, I., Eclache, V., Lefebvre, C., Leblond, V., Nguyen-Khac, F., Roos-Weil, D., 2023. **Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).** Haematologica 108, 1691–1696. <https://doi.org/10.3324/haematol.2022.282162> - **cat A - IF : 11.047**
3. Baldari, C.T., Valitutti, S., Dustin, M.L., 2023. **Editorial: Mechanisms of lymphocyte mediated cytotoxicity in health and disease.** Front Immunol 14, 1226870. <https://doi.org/10.3389/fimmu.2023.1226870> - **cat B - IF : 8.786**
4. Belaroussi, Y., Bouteiller, F., Bellera, C., Pasquier, D., Perol, M., Debieuvre, D., Filleron, T., Girard, N., Schott, R., Mathoulin-Pélissier, S., Martin, A.-L., Cousin, S., 2023. **Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting.** Sci Rep 13, 9584. <https://doi.org/10.1038/s41598-023-36623-1> - **cat C - IF : 4.996**
5. Bijok, B., Jaulin, F., Picard, J., Michelet, D., Fuzier, R., Arzalier-Daret, S., Basquin, C., Blanié, A., Chauveau, L., Cros, J., Delmas, V., Dupanloup, D., Gauss, T., Hamada, S., Le Guen, Y., Lopes, T., Robinson, N., Vacher, A., Valot, C., Pasquier, P., Blet, A., 2023. **Guidelines on human factors in critical situations 2023.** Anaesth Crit Care Pain Med 42, 101262. <https://doi.org/10.1016/j.accpm.2023.101262> - **cat B - IF : 7.025**

6. Blanc-Durand, F., Yaniz-Galende, E., Llop-Guevara, A., Genestie, C., Serra, V., Herencia-Ropero, A., Klein, C., Berton, D., Lortholary, A., Dohollou, N., Desauw, C., Fabbro, M., Malaurie, E., Bonichon-Lamaichhane, N., Dubot, C., Kurtz, J.E., de Rauglaudre, G., Raban, N., Chevalier-Place, A., Ferron, G., Kaminsky, M.-C., Kramer, C., Rouleau, E., Leary, A., 2023. **Corrigendum to “A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.”** Gynecol Oncol S0090-8258(23)00299–8. <https://doi.org/10.1016/j.ygyno.2023.05.058> - *cat B - IF : 5.304*

7. Boumaza, X., Lafaurie, M., Treiner, E., Walter, O., Pugnet, G., Martin-Blondel, G., Biotti, D., Ciron, J., Constantin, A., Tauber, M., Puisset, F., Moulis, G., Alric, L., Renaudineau, Y., Chauveau, D., Sailler, L., 2023. **Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases.** Int Immunopharmacol 120, 110342. <https://doi.org/10.1016/j.intimp.2023.110342> - *cat B - IF : 5.714*

8. Boutonnet, A., Pradines, A., Mano, M., Kreczman-Brun, M., Mazières, J., Favre, G., Ginot, F., 2023. **Size and Concentration of Cell-Free DNA Measured Directly from Blood Plasma, without Prior DNA Extraction.** Anal Chem. <https://doi.org/10.1021/acs.analchem.3c00998> - *cat A - IF : 8.008*

9. Courbiere, B., Poirot, C., Decanter, C., Rives, N., Huyghe, É., 2023. **[Restatement. Cancer and fertility preservation]**. Rev Prat 73, 557–560. – *cat E – IF : 1.412*

10. Delacourt, L., Allodji, R., Chappat, J., Haddy, N., El-Fayech, C., Demoor-Goldschmidt, C., Journy, N., Bolle, S., Thomas-Teinturier, C., Zidane, M., Rubino, C., Veres, C., Vu-Bezin, G., Berchery, D., Pluchart, C., Bondiau, P.-Y., Dumas, A., Bougas, N., Grill, J., Dufour, C., Fresneau, B., Pacquement, H., Diallo, I., Doz, F., de Vathaire, F., 2023. **Risk factors for obesity in adulthood among survivors of childhood cancer.** Obesity (Silver Spring). <https://doi.org/10.1002/oby.23784> - *cat A - IF : 9.298*

11. Dubucs, C., Chassaing, N., Khung-Savatovsky, S., Aziza, J., Courtade-Saïdi, M., 2023. **Artifacts and main lesions in fetal ocular histology.** Morphologie 107, 207–218. <https://doi.org/10.1016/j.morpho.2022.08.002> - *cat E - IF : 0.833*

12. El Fassi, N., Pavy le Traon, A., Mouchon, E., Rascol, O., Meissner, W.G., Foubert-Saumier, A., Gallois, Y., Tessier, S., Ory-Magne, F., Woisard, V.A., Fabbri, M., 2023. **UMSARS Versus Laryngoscopy-Based Assessment of Dysphagia.** Mov Disord Clin Pract 10, 974–979. <https://doi.org/10.1002/mdc3.13734> - *cat C - IF : 4.514*

13. Farge, T., Nakhle, J., Lagarde, D., Cognet, G., Polley, N., Castellano, R., Nicolau, M.-L., Bosc, C., Sabatier, M., Sahal, A., Saland, E., Jeanson, Y., Guiraud, N., Boet, E., Bergoglio,

C., Gotanègre, M., Mouchel, P.-L., Stuani, L., Larrue, C., Sallese, M., De Mas, V., Moro, C., Dray, C., Collette, Y., Raymond-Letron, I., Ader, I., Recher, C., Sarry, J.-E., Cabon, F., Vergez, F., Carriere, A., 2023. **CD36 drives metastasis and relapse in acute myeloid leukemia.** Cancer Res CAN-22-3682. <https://doi.org/10.1158/0008-5472.CAN-22-3682> - *cat A - IF : 13.312*

14. Feliu, V., Gomez-Roca, C., Michelas, M., Thébault, N., Lauzéral-Vizcaino, F., Salvioni, A., Scandella, L., Sarot, E., Valle, C., Balança, C.-C., Scarлата, C.-M., Delord, J.-P., Ayyoub, M. & Devaud, C., 2023. **Distant antimetastatic effect of enterotropic colon cancer-derived $\alpha 4\beta 7$ +CD8+ T cells.** Sci Immunol 8, eadg8841. <https://doi.org/10.1126/sciimmunol.adg8841> - *cat A - IF : 30.63*
15. Griessinger, E., Pereira-Martins, D., Nebout, M., Bosc, C., Saland, E., Boet, E., Sahal, A., Chiche, J., Debayle, D., Fleuriot, L., Puis, M., Mansat-De Mas, V., Vergez, F., Récher, C., Huls, G., Sarry, J.-E., Schuringa, J.J., Peyron, J.-F., 2023. **Oxidative phosphorylation fueled by fatty acid oxidation sensitizes leukemic stem cells to cold.** Cancer Res CAN-23-1006. <https://doi.org/10.1158/0008-5472.CAN-23-1006> - *cat A - IF : 13.312*
16. Guillet, S., Crickx, E., Azzaoui, I., Chappert, P., Boutin, E., Viallard, J.-F., Rivière, E., Gobert, D., Galicier, L., Malphettes, M., Cheze, S., Lefrere, F., Audia, S., Bonnotte, B., Lambotte, O., Noel, N., Fain, O., Moulis, G., Hamidou, M., Gerfaud-Valentin, M., Marolleau, J.-P., Terriou, L., Martis, N., Morin, A.-S., Perlat, A., Le Gallou, T., Roy-Peaud, F., Robbins, A., Lega, J.-C., Puyade, M., Comont, T., Limal, N., Languille, L., Zarrour, A., Luka, M., Menager, M., Belmondo, T., Hue, S., Canoui-Poitaine, F., Michel, M., Godeau, B., Mahévas, M., 2023. **Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.** Blood 141, 2867–2877. <https://doi.org/10.1182/blood.2022018665> - *cat A - IF : 25.476*
17. Guitton, C. & Cougoul, P., 2023. [Management of acute complications of sickle cell disease]. Rev Prat 73, 516–521. – *cat NC*
18. Héluain, V., Prévot, G., Cabarrou, B., Calvayrac, O., Taranchon-Clermont, E., Didier, A., Tabourier-Gouin, S., Milia, J., Mazières, J., 2023. **Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.** Respir Med Res 83, 100946. <https://doi.org/10.1016/j.resmer.2022.100946> - *cat D - IF : 3.149*
19. Hescot, S., Debien, V., Hadoux, J., Drui, D., Haissaguerre, M., de la Fouchardiere, C., Vezzosi, D., Do Cao, C., Libé, R., Le Tourneau, C., Baudin, E., Massard, C., du Rusquec, P., from the French ENDOCAN-COMETE network, 2023. **Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French**

network ENDOCAN-COMETE. Eur J Cancer S0959-8049(23)00248-4.
<https://doi.org/10.1016/j.ejca.2023.05.006> - *cat B - IF : 10.002*

20. Heudel, P.E., de Montfort, A., Debieuvre, D., Chouaid, C., Carton, M., Audigier-Valette, C., Filleron, T., Chabaud, S., Stancu, A., Quantin, X., Hiret, S., Bosquet, L., Blay, J.Y., 2023. **Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors.** Lung Cancer 182, 107280. <https://doi.org/10.1016/j.lungcan.2023.107280> - *cat B - IF : 6.081*

21. Kaphan, E., Bettega, F., Forcade, E., Labussière-Wallet, H., Fegueux, N., Robin, M., Peffault De Latour, R., Huynh, A., Lapierre, L., Berceanu, A., Marcais, A., Debureaux, P.-E., Vanlangendonck, N., Bulabois, C.-E., Magro, L., Daniel, A., Galtier, J., Lioure, B., Chevallier, P., Antier, C., Loschi, M., Guillermin, G., Mear, J.-B., Chantepie, S., Cornillon, J., Rey, G., Poire, X., Bazarbachi, A., Rubio, M.-T., Contentin, N., Orvain, C., Dulery, R., Bay, J.O., Croizier, C., Beguin, Y., Charbonnier, A., Skrzypczak, C., Desmier, D., Villate, A., Carré, M., Thiebaut-Bertrand, A., 2023. **Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.** Transplant Cell Ther 29, 362.e1-362.e12. <https://doi.org/10.1016/j.jtct.2023.02.020> - *cat B - IF : 5.609*

22. Kluger, N., Marcaillou, M., Sibaud, V., 2023. **Nivolumab-induced poliosis restricted to a tattoo: A coincidental association?** Ann Dermatol Venereol S0151-9638(23)00006-6. <https://doi.org/10.1016/j.annder.2023.01.002> - *cat E - IF : 0.934*

23. Le Cesne, A., Chevreau, C., Perrin, C., Italiano, A., Hervieu, A., Blay, J.Y., Piperno-Neumann, S., Saada-Bouazid, E., Bertucci, F., Firmin, N., Kalbacher, E., Narciso, B., Schiffler, C., Yara, S., Jimenez, M., Bouvier, C., Vidal, V., Chabaud, S., Duffaud, F., 2023. **Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.** ESMO Open 8, 101569. <https://doi.org/10.1016/j.esmoop.2023.101569> - *cat B - IF : 6.883*

24. Le Grand, S. & Karlin, L., 2023. **[New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy].** Bull Cancer S0007-4551(23)00090-5. <https://doi.org/10.1016/j.bulcan.2023.01.021> - *cat E - IF : 1.318*

25. Leong, W.S., Gowda, S., Jackson, R., Chabrilac, E., Edafe, O., 2023. **Superficial versus total parotidectomy for metastatic cutaneous squamous cell carcinoma and**

melanoma of the head and neck: a systematic review. J Laryngol Otol 137, 592–598.
<https://doi.org/10.1017/S0022215122001724> - *cat D - IF : 2.187*

26. Mazieres, J., Paik, P.K., Garassino, M.C., Le, X., Sakai, H., Veillon, R., Smit, E.F., Cortot, A.B., Raskin, J., Viteri, S., Wu, Y.-L., Yang, J.C.H., Ahn, M.-J., Ma, R., Zhao, J., O’Brate, A., Berghoff, K., Bruns, R., Otto, G., John, A., Felip, E., Thomas, M., 2023. **Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.** JAMA Oncol e231962. <https://doi.org/10.1001/jamaoncol.2023.1962> - *cat A - IF : 33.006*
27. Mesa, R., Verstovsek, S., Platzbecker, U., Gupta, V., Lavie, D., Giraldo, P., Recher, C., Kiladjian, J.-J., Oh, S.T., Gerds, A.T., Devos, T., Passamonti, F., Vannucchi, A.M., Egyed, M., Lech-Maranda, E., Pluta, A., Nilsson, L., Shimoda, K., McLornan, D., Kawashima, J., Klencke, B., Huang, M., Strouse, B., Harrison, C., 2023. **Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.** Haematologica. <https://doi.org/10.3324/haematol.2023.283106> - *cat A - IF : 11.047*
28. Munir, T., Moreno, C., Owen, C., Follows, G., Benjamini, O., Janssens, A., Levin, M.-D., Osterborg, A., Robak, T., Simkovic, M., Stevens, D., Voloshin, S., Vorobyev, V., Yagci, M., Ysebaert, L., Qi, K., Qi, Q., Parisi, L., Srinivasan, S., Schuier, N., Baeten, K., Howes, A., Caces, D.B., Niemann, C.U., Kater, A.P., 2023. **Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.** J Clin Oncol JCO2202283. <https://doi.org/10.1200/JCO.22.02283> - *cat A - IF : 50.717*
29. Noel-Savina, E., Dupuis, M., Prévot, G., Mazières, J., Didier, A., 2023. **Reply to Gille and collaborators: DM and VC impairment after COVID-1.** Respir Med Res 83, 100956. <https://doi.org/10.1016/j.resmer.2022.100956> - *cat D - IF : 3.149*
30. Noortman, W.A., Aide, N., Vriens, D., Arkes, L.S., Slump, C.H., Boellaard, R., Goeman, J.J., Deroose, C.M., Machiels, J.-P., Licitra, L.F., Lhommel, R., Alessi, A., Woff, E., Goffin, K., Le Tourneau, C., Gal, J., Temam, S., Delord, J.-P., van Velden, F.H.P., de Geus-Oei, L.-F., 2023. **Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer.** Cancers (Basel) 15, 2681. <https://doi.org/10.3390/cancers15102681> - *cat B - IF : 6.575*
31. Ocio, E.M., Perrot, A., Bories, P., San-Miguel, J.F., Blau, I.W., Karlin, L., Martinez-Lopez, J., Wang, S.-Y., Bringhen, S., Marcatti, M., Mateos, M.-V., Rodriguez-Otero, P., Oliva, S., Nogai, A., Le Roux, N., Dong, L., Macé, S., Gassiot, M., Fitzmaurice, T., Oprea, C., Moreau, P., 2023. **Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma**

ineligible/with no immediate intent for autologous stem cell transplantation.
Leukemia 1–9. <https://doi.org/10.1038/s41375-023-01936-7> - *cat A* - *IF* : 12.883

32. Orlando, V., Drubay, D., Lavaud, P., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka, M., Laguerre, B., Fléchon, A., Grosse-Goupil, M., Cojean-Zelek, I., Oudard, S., Labourey, J.-L., Chinet-Charrot, P., Legouffe, E., Lagrange, J.-L., Linassier, C., Deplanque, G., Beuzeboc, P., Davin, J.-L., Martin, A.-L., Brihoum, M., Culine, S., Teuff, G.L., Fizazi, K., 2023. **Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.** Clin Genitourin Cancer S1558-7673(23)00104–0. <https://doi.org/10.1016/j.clgc.2023.05.003> - *cat C* - *IF* : 3.121
33. Ortiz-Muñoz, G., Brown, M., Carbone, C.B., Pechuan-Jorge, X., Rouilly, V., Lindberg, H., Ritter, A.T., Raghupathi, G., Sun, Q., Nicotra, T., Mantri, S.R., Yang, A., Doerr, J., Nagarkar, D., Darmanis, S., Haley, B., Mariathasan, S., Wang, Y., Gomez-Roca, C., de Andrea, C.E., Spigel, D., Wu, T., Delamarre, L., Schöneberg, J., Modrusan, Z., Price, R., Turley, S.J., Mellman, I., Moussion, C., 2023. **In situ tumour arrays reveal early environmental control of cancer immunity.** Nature. <https://doi.org/10.1038/s41586-023-06132-2> - *cat A+* - *IF* : 69.504
34. Poumeaud, F., Valentin, T., Vande Perre, P., Jaffrelot, M., Bonnet, B., Chibon, F., Chevreau, C., Selves, J., Guimbaud, R., Fares, N., 2023. **Special features of sarcomas developed in patients with Lynch syndrome: a systematic review.** Crit Rev Oncol Hematol 104055. <https://doi.org/10.1016/j.critrevonc.2023.104055> - *cat B* - *IF* : 6.625
35. Royer, B., Launay, M., Ciccolini, J., Derain, L., Parant, F., Thomas, F., Guitton, J., 2023. **Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.** ESMO Open 8, 101577. <https://doi.org/10.1016/j.esmoop.2023.101577> - *cat B* - *IF* : 6.883
36. Sargos, P., Le Guevelou, J., Khalifa, J., Albiges, L., Azria, D., de Crevoisier, R., Supiot, S., Créhange, G., Roubaud, G., Chapet, O., Pasquier, D., Blanchard, P., Latorzeff, I., 2023. **The role of radiation therapy for de novo metastatic bladder and renal cancers.** Cancer Radiother S1278-3218(23)00097–5. <https://doi.org/10.1016/j.canrad.2023.02.004> - *cat E* - *IF* : 1.217
37. Scholaert, M., Houmadi, R., Martin, J., Serhan, N., Tauber, M., Braun, E., Basso, L., Merle, E., Descargues, P., Viguier, M., Lesort, C., Chaput, B., Kanitakis, J., Jullien, D., Livideanu, C.B., Lamant, L., Pagès, E., Gaudenzio, N., 2023. **3D deconvolution of human**

skin immune architecture with Multiplex Annotated Tissue Imaging System. Sci Adv 9, eadf9491. <https://doi.org/10.1126/sciadv.adf9491> - *cat A - IF : 14.957*

38. Solomon, B.J., Bauer, T.M., K Mok, T.S., Liu, G., Mazieres, J., Marinis, F. de, Goto, Y., Kim, D.-W., Wu, Y.-L., Jassem, J., López, F.L., Soo, R.A., Shaw, A.T., Polli, A., Messina, R., Iadeluca, L., Toffalorio, F., Felip, E., 2023. **Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.** Future Oncol. <https://doi.org/10.2217/fon-2022-1289> - *cat D - IF : 3.674*
39. Stadler, J.-C., Keller, L., Mess, C., Bauer, A.T., Koett, J., Geidel, G., Heidrich, I., Vidal-Y-Sy, S., Andreas, A., Stramaglia, C., Sementsov, M., Haberstroh, W., Deitert, B., Hoehne, I.L., Reschke, R., Haalck, T., Pantel, K., Gebhardt, C., Schneider, S.W., 2023. **Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.** J Immunother Cancer 11, e006456. <https://doi.org/10.1136/jitc-2022-006456> - *cat A - IF : 12.469*
40. Taprogge, J., Vergara-Gil, A., Leek, F., Abreu, C., Vávrová, L., Carnegie-Peake, L., Schumann, S., Eberlein, U., Lassmann, M., Schurrat, T., Luster, M., Verburg, F.A., Vallot, D., Vija, L., Courbon, F., Newbold, K., Bardies, M., Flux, G., 2023. **Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.** Eur J Nucl Med Mol Imaging 1–10. <https://doi.org/10.1007/s00259-023-06295-0> - *cat A - IF : 10.057*
41. Tran, M.L., Borie-Guichot, M., Garcia, V., Oukhrib, A., Génisson, Y., Levade, T., Ballereau, S., Turrin, C.-O., Dehoux, C., 2023. **Phosphorus Dendrimers for Metal-Free Ligation: Design of Multivalent Pharmacological Chaperones against Gaucher Disease.** Chemistry e202301210. <https://doi.org/10.1002/chem.202301210> - *cat C - IF : 5.02*
42. Turner, N.C., Oliveira, M., Howell, S.J., Dalenc, F., Cortes, J., Gomez Moreno, H.L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., Morales Murillo, S., Okera, M., Park, Y.H., Sohn, J., Toi, M., Tokunaga, E., Yousef, S., Zhukova, L., de Bruin, E.C., Grinsted, L., Schiavon, G., Foxley, A., Rugo, H.S., CAPItello-291 Study Group [Inv: Dalenc, F.], 2023. **Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.** N Engl J Med 388, 2058–2070. <https://doi.org/10.1056/NEJMoa2214131> - *cat A+ - IF : 176.079*
43. Valette, C.A., Filleron, T., Debieuvre, D., Lena, H., Pérol, M., Chouaid, C., Simon, G., Quantin, X., Girard, N., 2023. **Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the**

era of immunotherapy. Respir Med Res 84, 101012. <https://doi.org/10.1016/j.resmer.2023.101012> - cat D - IF : 3.149

44. Verstraete, N., Marku, M., Domagala, M., Arduin, H., Bordenave, J., Fournié, J.-J., Ysebaert, L., Poupot, M. & Pancaldi, V., 2023. **An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia.** iScience 26, 106897. <https://doi.org/10.1016/j.isci.2023.106897> - cat B - IF : 6.107

45. Villeneuve, T., Chevreau, C., Pontier, S., Prévot, G., Rochaix, P., Courtade-Saidi, M., Guibert, N., 2023. **EBUS-TBNA for the diagnosis of primary pulmonary artery sarcoma.** Respir Med Res 83, 100974. <https://doi.org/10.1016/j.resmer.2022.100974> - cat D – IF : 3.149



